According to the latest market research study published by P&S Intelligence, the global cardiac safety services market, valued at USD 811 million in 2024, is poised for remarkable growth, expanding at a robust CAGR of 14.1% from 2025 to 2032 and expected to reach USD 2,305.1 million by 2032. This surge is fueled by the increasing demand for advanced cardiac monitoring solutions in clinical trials and research studies, ensuring comprehensive heart protection across all phases of drug development.
Download free Report Sample Now
The growing number of drug launches and clinical trials,
rising healthcare expenditures, strategic investments by pharmaceutical
companies, and the emergence of high-tech healthcare products are key drivers
of this market. Moreover, an aging population and sedentary lifestyles among
millennials are significantly boosting the need for cardiac safety solutions.
The COVID-19 pandemic further highlighted the importance of
heart health, as the virus has been linked to a range of serious cardiovascular
conditions. Studies, including a 2022 BMJ report, indicate that COVID-19
patients face elevated risks of heart failure, stroke, myocardial infarction,
and arrhythmias, driving increased demand for cardiac safety monitoring.
Trends Shaping the Market:
- Artificial
Intelligence (AI) and Machine Learning (ML): AI and ML are
revolutionizing cardiac safety by enabling faster, more accurate analysis
of ECGs, cardiac events, and wearable device data. AI-driven solutions
enhance real-time monitoring, improve patient safety, and support
personalized medicine.
- Rising
Prevalence of Cardiovascular Diseases (CVDs): With CVDs responsible
for nearly 20 million deaths globally each year, the demand for advanced
monitoring, including ECG/Holter and blood pressure measurement services,
is rising sharply.
- Decentralized
and Virtual Clinical Trials: Remote monitoring solutions are
increasingly essential, with AI technologies facilitating real-time
cardiac analysis and improved trial outcomes.
Market Segmentation Highlights:
- Type:
Integrated services dominate with an 80% market share in 2024, providing
end-to-end cardiac safety solutions for pharmaceutical and
biopharmaceutical companies. Standalone services, however, are
experiencing rapid growth.
- Service:
ECG/Holter monitoring led with a 65% market share in 2024, while blood
pressure measurement services are projected to grow the fastest due to the
increasing prevalence of hypertension.
- End-Use:
Pharmaceutical and biopharmaceutical companies represent 75% of the
market, with contract research organizations (CROs) showing the highest
growth due to outsourcing trends and adoption of advanced cardiac safety
tools.
- Region:
North America leads with a 40% market share, driven by technological
advancements and high healthcare expenditure, while Europe is projected to
grow at the fastest CAGR due to its advanced healthcare infrastructure and
aging population.
Industry Leaders Driving Innovation:
Key players such as Koninklijke Philips N.V., IQVIA, Medpace Inc., Ncardia, Eurofins Scientific SE, and others are leveraging AI-powered solutions and advanced cardiac imaging technologies to enhance patient safety and accelerate drug development. Recent innovations include AI-driven cardiac MRI systems, compact ultrasound enhancements, and mobile Holter monitoring solutions.
The cardiac safety services market is poised for a transformative decade, driven by technological innovation, rising cardiovascular disease prevalence, and increasing demand for accurate, real-time heart monitoring. Companies investing in AI-powered, integrated, and patient-focused solutions are well-positioned to lead the charge in improving cardiac health worldwide.
